{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:32:36Z","timestamp":1792845156499,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["STEPHE24A0"],"award-info":[{"award-number":["STEPHE24A0"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100020895","name":"Temerty Faculty of Medicine, University of Toronto","doi-asserted-by":"publisher","award":["Bone&MineralGroup"],"award-info":[{"award-number":["Bone&MineralGroup"]}],"id":[{"id":"10.13039\/http:\/\/dx.doi.org\/10.13039\/501100020895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"DOI":"10.1007\/s00198-026-08243-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T11:15:31Z","timestamp":1792754131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Longitudinal changes in bone mineral density among adults with cystic fibrosis: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6712-3940","authenticated-orcid":false,"given":"Arunan","family":"Selvarajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viethushaa","family":"Mohandas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Sykes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Jad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa J.","family":"Strug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Batt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Stephenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"8243_CR1","unstructured":"Cystic Fibrosis Canada. 2023 Annual Data Report. (2024)"},{"key":"8243_CR2","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton PG et al (2019) Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med 381:1809\u20131819","journal-title":"N Engl J Med"},{"key":"8243_CR3","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02029-2022","volume":"62","author":"CL Daines","year":"2023","unstructured":"Daines CL et al (2023) Long-term safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study. Eur Respir J 62:2202029","journal-title":"Eur Respir J"},{"key":"8243_CR4","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","volume":"22","author":"JK Bower","year":"2023","unstructured":"Bower JK et al (2023) Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study. J Cyst Fibros 22:730\u2013737","journal-title":"J Cyst Fibros"},{"key":"8243_CR5","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00174-2023","volume":"62","author":"F Frost","year":"2023","unstructured":"Frost F et al (2023) Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study. Eur Respir J 62:2300174","journal-title":"Eur Respir J"},{"key":"8243_CR6","volume":"6","author":"RL Boyle","year":"2022","unstructured":"Boyle RL et al (2022) Prevalence and risk factors for low bone mineral density in adults with cystic fibrosis. JBMR 6:e10666","journal-title":"JBMR"},{"key":"8243_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-9-125","volume":"9","author":"A Papaioannou","year":"2008","unstructured":"Papaioannou A et al (2008) Longitudinal analysis of vertebral fracture and BMD in a Canadian cohort of adult cystic fibrosis patients. BMC Musculoskelet Disord 9:125","journal-title":"BMC Musculoskelet Disord"},{"key":"8243_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-009-9316-9","volume":"86","author":"J Paccou","year":"2010","unstructured":"Paccou J, Zeboulon N, Combescure C, Gossec L, Cortet B (2010) The prevalence of osteoporosis, osteopenia, and fractures among adults with cystic fibrosis: a systematic literature review with meta-analysis. Calcif Tissue Int 86:1\u20137","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 2","key":"8243_CR9","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/S1569-1993(11)60004-0","volume":"10","author":"I Sermet-Gaudelus","year":"2011","unstructured":"Sermet-Gaudelus I et al (2011) European cystic fibrosis bone mineralisation guidelines. J Cyst Fibros 10(Suppl 2):S16\u2013S23","journal-title":"J Cyst Fibros"},{"key":"8243_CR10","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1210\/jc.2004-1629","volume":"90","author":"RM Aris","year":"2005","unstructured":"Aris RM et al (2005) Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 90:1888\u20131896","journal-title":"J Clin Endocrinol Metab"},{"key":"8243_CR11","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/01.med.0000436191.87727.ec","volume":"20","author":"MS Stalvey","year":"2013","unstructured":"Stalvey MS, Clines GA (2013) Cystic fibrosis-related bone disease: insights into a growing problem. Curr Opin Endocrinol Diab Obes 20:547\u2013552","journal-title":"Curr Opin Endocrinol Diab Obes"},{"key":"8243_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","volume":"34","author":"D Weill","year":"2015","unstructured":"Weill D et al (2015) A consensus document for the selection of lung transplant candidates: 2014-an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transpl 34:1\u201315","journal-title":"J Heart Lung Transpl"},{"key":"8243_CR13","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.21037\/jtd-2021-09","volume":"13","author":"A Arjuna","year":"2021","unstructured":"Arjuna A, Olson MT, Walia R (2021) Current trends in candidate selection, contraindications, and indications for lung transplantation. J Thorac Dis 13:6514\u20136527","journal-title":"J Thorac Dis"},{"key":"8243_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00259-024-06912-6","volume":"52","author":"R Slart","year":"2025","unstructured":"Slart R et al (2025) Updated practice guideline for dual-energy X-ray absorptiometry (DXA). Eur J Nucl Med Mol Imaging 52:539\u2013563","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8243_CR15","unstructured":"Wilcox P, Waters I (2018) Cystic Fibrosis Care Guidelines for CF-Related Bone Disease"},{"key":"8243_CR16","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1002\/jbmr.95","volume":"25","author":"C Berger","year":"2010","unstructured":"Berger C et al (2010) Peak bone mass from longitudinal data: implications for the prevalence, pathophysiology, and diagnosis of osteoporosis. J Bone Min Res 25:1948\u20131957","journal-title":"J Bone Min Res"},{"key":"8243_CR17","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver CM et al (2016) The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int 27:1281\u20131386","journal-title":"Osteoporos Int"},{"key":"8243_CR18","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1503\/cmaj.071416","volume":"178","author":"C Berger","year":"2008","unstructured":"Berger C et al (2008) Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents. CMAJ 178:1660\u20131668","journal-title":"CMAJ"},{"key":"8243_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1164\/rccm.200307-1049OC","volume":"169","author":"RM Aris","year":"2004","unstructured":"Aris RM et al (2004) Efficacy of alendronate in adults with cystic fibrosis with low bone density. Am J Respir Crit Care Med 169:77\u201382","journal-title":"Am J Respir Crit Care Med"},{"key":"8243_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.jcf.2011.07.007","volume":"10","author":"CS Haworth","year":"2011","unstructured":"Haworth CS et al (2011) Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis. J Cyst Fibros 10:470\u2013476","journal-title":"J Cyst Fibros"},{"key":"8243_CR21","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/thx.2002.002568","volume":"59","author":"SP Conway","year":"2004","unstructured":"Conway SP, Oldroyd B, Morton A, Truscott JG, Peckham DG (2004) Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax 59:699\u2013703","journal-title":"Thorax"},{"key":"8243_CR22","volume":"1","author":"TC Jeffery","year":"2023","unstructured":"Jeffery TC, Chang AB, Conwell LS (2023) Bisphosphonates for osteoporosis in people with cystic fibrosis. Cochrane Database Syst Rev 1:CD002010","journal-title":"Cochrane Database Syst Rev"},{"key":"8243_CR23","doi-asserted-by":"crossref","unstructured":"Selvarajah, A, Dittrich, A, Mohandas, V, Sykes, J & Stephenson, AL Longitudinal changes in bone mineral density among adults with cystic fibrosis: a systematic review and meta-analysis. CRD420251091118 (PROSPERO, 2025)","DOI":"10.1007\/s00198-026-08243-8"},{"key":"8243_CR24","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71","journal-title":"BMJ"},{"key":"8243_CR25","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/JBIES-22-00430","volume":"21","author":"TH Barker","year":"2023","unstructured":"Barker TH et al (2023) The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. JBI Evid Synth 21:494\u2013506","journal-title":"JBI Evid Synth"},{"key":"8243_CR26","doi-asserted-by":"crossref","unstructured":"Moola S, et al Chapter 7: Systematic reviews of etiology and risk. In: Aromataris E, Munn Z (Editors). (Joanna Briggs Institute for Evidence Synthesis, 2020)","DOI":"10.46658\/JBIRM-17-06"},{"key":"8243_CR27","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <https:\/\/www.R-project.org\/>. (2025)"},{"key":"8243_CR28","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.jcf.2004.08.002","volume":"3","author":"CS Haworth","year":"2004","unstructured":"Haworth CS, Jones AM, Adams JE, Selby PL, Webb AK (2004) Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis. J Cyst Fibros 3:233\u2013236","journal-title":"J Cyst Fibros"},{"key":"8243_CR29","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1378\/chest.08-0608","volume":"134","author":"A Papaioannou","year":"2008","unstructured":"Papaioannou A et al (2008) Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). Chest 134:794\u2013800","journal-title":"Chest"},{"key":"8243_CR30","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1365-2265.2008.03434.x","volume":"70","author":"I Chapman","year":"2009","unstructured":"Chapman I et al (2009) Intravenous zoledronate improves bone density in adults with cystic fibrosis (CF). Clin Endocrinol (Oxf) 70:838\u2013846","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8243_CR31","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1093\/jbmr\/zjae139","volume":"39","author":"R Jad","year":"2024","unstructured":"Jad R et al (2024) Longitudinal changes in BMD in adults with cystic fibrosis. J Bone Min Res 39:1716\u20131721","journal-title":"J Bone Min Res"},{"key":"8243_CR32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1136\/thorax.57.8.719","volume":"57","author":"CS Haworth","year":"2002","unstructured":"Haworth CS et al (2002) A prospective study of change in bone mineral density over one year in adults with cystic fibrosis. Thorax 57:719\u2013723","journal-title":"Thorax"},{"key":"8243_CR33","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1542\/peds.114.2.435","volume":"114","author":"E Gronowitz","year":"2004","unstructured":"Gronowitz E, Mellstrom D, Strandvik B (2004) Normal annual increase of bone mineral density during two years in patients with cystic fibrosis. Pediatrics 114:435\u2013442","journal-title":"Pediatrics"},{"key":"8243_CR34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0022-3476(98)70172-6","volume":"133","author":"G Bhudhikanok","year":"1998","unstructured":"Bhudhikanok G et al (1998) Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J Pediatrics 133:18\u201327","journal-title":"J Pediatrics"},{"key":"8243_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-4-13","volume":"4","author":"C Brenckmann","year":"2003","unstructured":"Brenckmann C et al (2003) Osteoporosis in Canadian adult cystic fibrosis patients: A descriptive study. BMC Musculoskelet Disord 4:13","journal-title":"BMC Musculoskelet Disord"},{"issue":"Suppl 2","key":"8243_CR36","doi-asserted-by":"publisher","first-page":"S48","DOI":"10.1016\/j.jcf.2019.08.018","volume":"18","author":"A Anabtawi","year":"2019","unstructured":"Anabtawi A, Le T, Putman M, Tangpricha V, Bianchi ML (2019) Cystic fibrosis bone disease: Pathophysiology, assessment and prognostic implications. J Cyst Fibros 18(Suppl 2):S48\u2013S55","journal-title":"J Cyst Fibros"},{"key":"8243_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/aje\/kwf049","volume":"156","author":"KE Bainbridge","year":"2002","unstructured":"Bainbridge KE, Sowers MF, Crutchfield M, Lin X, Jannausch M (2002) Natural history of bone loss over 6 years among premenopausal and early postmenopausal women. Am J Epidemiol 156:410\u2013417","journal-title":"Am J Epidemiol"},{"key":"8243_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s001980200001","volume":"13","author":"L Warming","year":"2002","unstructured":"Warming L, Hassager C, Christiansen C (2002) Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int 13:105\u2013112","journal-title":"Osteoporos Int"},{"key":"8243_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archinte.164.6.603","volume":"164","author":"ML Gourlay","year":"2004","unstructured":"Gourlay ML, Brown SA (2004) Clinical considerations in premenopausal osteoporosis. Arch Intern Med 164:603\u2013614","journal-title":"Arch Intern Med"},{"key":"8243_CR40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.bone.2008.07.236","volume":"43","author":"H Blain","year":"2008","unstructured":"Blain H et al (2008) Cortical and trabecular bone distribution in the femoral neck in osteoporosis and osteoarthritis. Bone 43:862\u2013868","journal-title":"Bone"},{"key":"8243_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ogc.2011.07.001","volume":"38","author":"JC Lo","year":"2011","unstructured":"Lo JC, Burnett-Bowie SA, Finkelstein JS (2011) Bone and the perimenopause. Obstet Gynecol Clin North Am 38:503\u2013517","journal-title":"Obstet Gynecol Clin North Am"},{"key":"8243_CR42","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.ogc.2018.07.012","volume":"45","author":"AS Karlamangla","year":"2018","unstructured":"Karlamangla AS, Burnett-Bowie SM, Crandall CJ (2018) Bone health during the menopause transition and beyond. Obstet Gynecol Clin North Am 45:695\u2013708","journal-title":"Obstet Gynecol Clin North Am"},{"key":"8243_CR43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1136\/thx.2006.075887","volume":"62","author":"EF Shead","year":"2007","unstructured":"Shead EF et al (2007) Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 62:650\u2013651","journal-title":"Thorax"},{"key":"8243_CR44","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1016\/j.ajpath.2012.01.039","volume":"180","author":"C Le Henaff","year":"2012","unstructured":"Le Henaff C et al (2012) The F508del mutation in cystic fibrosis transmembrane conductance regulator gene impacts bone formation. Am J Pathol 180:2068\u20132075","journal-title":"Am J Pathol"},{"key":"8243_CR45","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1164\/rccm.201312-2144LE","volume":"189","author":"F Velard","year":"2014","unstructured":"Velard F et al (2014) Cystic fibrosis and bone disease: defective osteoblast maturation with the F508del mutation in cystic fibrosis transmembrane conductance regulator. Am J Respir Crit Care Med 189:746\u2013748","journal-title":"Am J Respir Crit Care Med"},{"key":"8243_CR46","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00198-015-3343-3","volume":"27","author":"J Jacquot","year":"2016","unstructured":"Jacquot J, Delion M, Gangloff S, Braux J, Velard F (2016) Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. Osteoporos Int 27:1401\u20131412","journal-title":"Osteoporos Int"},{"key":"8243_CR47","doi-asserted-by":"publisher","first-page":"e1248","DOI":"10.1210\/clinem\/dgaa890","volume":"106","author":"MS Putman","year":"2021","unstructured":"Putman MS et al (2021) The effects of ivacaftor on bone density and microarchitecture in children and adults with cystic fibrosis. J Clin Endocrinol Metab 106:e1248\u2013e1261","journal-title":"J Clin Endocrinol Metab"},{"key":"8243_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ppul.26243","volume":"58","author":"M Gur","year":"2023","unstructured":"Gur M et al (2023) Effect of Trikafta on bone density, body composition and exercise capacity in CF: a pilot study. Pediatr Pulmonol 58:577\u2013584","journal-title":"Pediatr Pulmonol"},{"key":"8243_CR49","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s00198-026-07925-7","volume":"37","author":"JA Kanis","year":"2026","unstructured":"Kanis JA et al (2026) Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX. Osteoporos Int 37:1067\u20131085","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08243-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08243-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-08243-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:02:30Z","timestamp":1792800150000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-08243-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":49,"alternative-id":["8243"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-08243-8","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"6 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ALS receives grant funding from the Cystic Fibrosis Foundation, Cystic Fibrosis Canada, and CIHR. ALS receives consulting fees from Vertex Pharmaceuticals. ALS has received honoraria for lectures, presentations, or educational events from Vertex Pharmaceuticals, Viatris, and GSK. ALS has received travel support from Vertex Pharmaceuticals and Viatris. ALS serves as Medical Director of the Canadian CF Registry for Cystic Fibrosis Canada. AS, AD, VM, JS, RJ, LJS, GB, and JB declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}